NLS Alligator Bioscience

Alligator Bioscience has announced the initiation a sponsored research collaboration to study biomarker data from Alligator’s OPTIMIZE-1 study with the University of Pennsylvania’s (UPENN) Pancreatic Cancer Research Center. Gregory Beatty, assistant professor of Medicine in the Division of Hematology/Oncology, UPENN, will serve as the faculty investigator for the sponsored Research agreements. Data analysis by Dr. […]

Alligator Bioscience and Scandion Oncology have announced the conclusion of their collaboration with a very positive outcome. The purpose of the collaboration was to explore the anti-tumor efficacy of the CD40 antibody mitazalimab in chemotherapy-resistant preclinical tumor models as an addition to chemotherapy (FOLFIRINOX) combined with SCO-101. The hypothesis that was tested was to see […]

Alligator Bioscience has entered into a research collaboration and license agreement with Orion Corporation to discover and develop together new bispecific antibody cancer therapeutics. The research collaboration will focus on the discovery of novel bispecific antibodies directed towards immuno-oncology targets selected by Orion. The agreement covers an option to develop three bispecific antibodies. Under the […]

The two companies have entered into a joint research agreement. Under the agreement, Alligator will employ its antibody generation technologies in collaboration with BioArctic to develop new product candidates, it states in a press release. “We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully […]

Alligator Bioscience has entered into a joint research collaboration with MacroGenics to develop novel immunotherapy. The research collaboration will lead to the expansion of Alligator’s patient specific immunotherapy Neo-X-Prime by incorporating MacroGenics’ DART and TRIDENT multi-specific platforms against two undisclosed targets, reveals the company in a press release. “The aim is to create a drug […]

The Board of Directors of the company has appointed Søren Bregenholt as new Chief Executive Officer (CEO). He is appointed to strengthen Alligator’s business development activities and clinical progress on an international level, state the company in a press release. Bregenholt will take up the position on 1 June 2021, succeeding Per Norlén, who will […]